KINIKSA

Every Second Counts!™

KPL-716 Ph1b Part 4
Repeated-Single-Dose Interim Results

Interim KPL-716 Part 4 Repeated-Single-Dose Summary

Enrolled 43 subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus

- Randomized 1:1 between weekly subcutaneous (SC) injections of either placebo or 360mg of KPL-716 for 12 weeks
- Interim data includes all subjects through the 12-week treatment period

Primary endpoint: safety and tolerability of KPL-716

Exploratory endpoints:

- Worst-Itch Numerical Rating Score (WI-NRS) as recorded in a daily e-diary
- Measures of atopic dermatitis disease severity

Topline Observations:

- KPL-716 showed rapid and sustained reductions in pruritus versus placebo for the duration of the treatment period
    - The mean change from baseline in weekly-average WI-NRS at Week 1 was -28.1% in KPL-716 recipients compared to -6.8% in placebo recipients
    - The mean change from baseline in weekly-average WI-NRS at Week 12 was -55.0% in KPL-716 recipients compared to -30.9% in placebo recipients
    - 52.6% of KPL-716 recipients demonstrated a ≥ 4-point reduction in weekly-average WI-NRS at Week 12 compared to 26.3% of placebo recipients
- There were no meaningful benefits of repeated-single-doses of KPL-716 on other efficacy endpoints specific to atopic dermatitis, including Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD)
- There were no serious adverse events. However, there were more atopic dermatitis flares in KPL-716 recipients compared to placebo recipients (47.6% for the KPL-716 arm vs. 4.5% for the placebo arm) through the 12-week treatment period. KPL-716 was otherwise well-tolerated

KPL-716 placebo-controlled repeated-single-dose Phase 1b study design in patients with moderate-to-severe atopic dermatitis

Key Inclusion Criteria:
- IGA of 3 or 4
- BSA ≥ 10%
- EASI ≥ 12
- WI-NRS ≥7 at SV1
- WI-NRS ≥5 at d0



SV1: Screening Visit 1; **SV2**: Screening Visit 2; **D0**: Day 0; **SC**: Subcutaneous; **TCS:** Topical corticosteroid

Baseline Subject & Disease Characteristics

PBO (All Subjects)
KPL-716 (All Subjects)

Baseline Subject Characteristics











Baseline Disease Characteristics









ULN: Upper Limit of Normal; **PBO**: Placebo; **TCS:** Topical corticosteroid

Overview of treatment-emergent adverse events (TEAE) through 12-week treatment period

TEAE Overview

	Placebo (N=22)	KPL-716 (N=21)
Any TEAE	12 (54.5%)	18 (85.7%)
Any Drug-Related TEAE	4 (18.2%)	8 (38.1%)
Any Moderate or Severe TEAE	6 (27.3%)	11 (52.4%)
Any Drug-Related Moderate or Severe TEAE	0	2 (9.5%)
Any Treatment-Emergent Serious AE	0	0
Any Drug-Related Serious TEAE	0	0
Any Atopic Dermatitis Flare-Related TEAE	1 (4.5%)	10 (47.6%)
Any Injection Site Reaction	2 (9.1%)	3 (14.3%)
Any TEAE Led to Dose Interruptions	1 (4.5%)	2 (9.5%)
Any TEAE Led to Study Drug Discontinuation	0	2 (9.5%)
Any TEAE Led to Death	0	0

Moderate / Severe Drug-Related TEAE

	Placebo (N=22)	KPL-716 (N=21)
Subjects with At Least 1 Drug-related Moderate or Severe TEAE	0	2 (9.5%)
Infections and infestations	0	1 (4.8%)
Eczema impetiginous	0	1 (4.8%)
Psychiatric disorders	0	1 (4.8%)
Depression	0	1 (4.8%)
Skin and subcutaneous tissue disorders	0	1 (4.8%)
Dermatitis atopic	0	1 (4.8%)

KPL-716 showed rapid and sustained reduction in pruritus versus placebo despite more flares in the active treatment arm





Note: Placebo TCS rescue curve is n=1
Note: y-axis is different from chart on the left

RSC: PLB - Rescue TCS used in placebo arm
RSC: KPL – Rescue TCS used in KPL-716 arm
Note: Based on full interim data set as of 1st database lock

A larger percentage of subjects in the KPL-716 arm achieved a ≥4 point change in weekly average WI-NRS versus Placebo





Baseline Subject Characteristics & Retrospective Groupings



Note: Based on full interim data set as of 1st database lock

ULN: Upper Limit of Normal; **PBO**: Placebo; **TCS:** Topical corticosteroid

Disease Characteristics at Baseline & Retrospective Groupings

PBO (All)
716 (All)
KPL-716 (Subjects Who Did NOT Flare)
KPL-716 (Experienced a Flare)

Mean WI-NRS



Mean EASI Scores Before Dosing



Mean Body Surface Area Before Dosing



Median WI-NRS



Median EASI Scores Before Dosing



Median Body Surface Area Before Dosing



Note: Based on full interim data set as of 1st database lock
SV1: Screening Visit 1; **SV2**: Screening Visit 2; **BL**: Baseline on Day 0 before first dose of KPL-716; **TCS**: Topical Corticosteroid; **PBO:** Placebo

Every Second Counts!™